Zhejiang Huakang Pharmaceutical Co Ltd (605077) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Zhejiang Huakang Pharmaceutical Co Ltd stock ¥11.25, price ¥10.36, upside +8.6%, quality 46 out of 100. Rating: fairly valued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ¥9.85 – ¥23.71 · fair‑value band ¥8.44 – ¥14.06 · the ¥10.36 price screens below the ¥11.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Zhejiang Huakang Pharmaceutical Co in your weekly email
Every Wednesday you see whether Zhejiang Huakang Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide.
Show moreShow less
It offers polyols products such as xylitol, is a polyol that occurs naturally regular sugar raise blood sugar levels; sorbitol, is produced by the catalytic hydrogenation of D-glucose and is available as a free-flowing crystalline powder, and as aqueous solutions; maltitol a bulk sweetener produced from naturally occurring compounds in corn; erythritol, is produced by the enzymatic hydrolysis of starch into glucose, non-caloric, non-hygroscopic excipient with excellent sweet taste and cooling effect; lactitol is produced by hydrogenation of lactose; mannitol is derived from enzymatic hydrolysis of starch; isomalt is produced from sucrose as a raw material and transformed into isomaltulose by sucrose isomerase.
In addition, the company offers starch sugar provide high fructose, glucose, maltose syrups, maltodextrin; as well as rare sugar d- xylose, and l-arabinose; and dietary fiber include polydextrose. Zhejiang Huakang Pharmaceutical Co., Ltd. was founded in 2001 and is based in Quzhou, China.
Stock analysis
Zhejiang Huakang Pharmaceutical Co Ltd (605077) currently trades at ¥10.36, while our model-based Fair Value estimate is ¥11.25, so the stock looks roughly fairly valued today (gap 7.9%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥19.05 per share, and 10 of the 16 models we run sit above the ¥10.36 price.
Bear case: the Asset-Based group reads lowest at ¥5.75, and 6 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥8.44 (bear) to ¥14.06 (bull), the price of ¥10.36 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Zhejiang Huakang Pharmaceutical Co Ltd reported revenue of 4.2B CNY in FY2025 versus 1.6B CNY in FY2021, a compound +27.3%/yr. Reported net income was 200M CNY in FY2025, compounding −4.1%/yr from FY2021.
Key figures
Market cap 3.1B CNY (≈ $471M) Small · P/E ratio 29.6 · P/S ratio 0.65 · EPS (TTM) ¥0.3500 · Dividend yield 2.9% · Net margin 2.3% · Return on equity 3.4% · Return on assets (EBIT) 6.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −25% fair-value upside, at 9%, 605077 screens cheaper than that median.
Fair Value models
Bear¥8.44Fair Value ¥11.25Bull¥14.06
Price ¥10.36 · Upside +8.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0427 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+49.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.0%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−2.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.2%
Dividend (yield on the price)2.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−11.4% vs 16.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 8%
Compare Zhejiang Huakang Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 336 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside+8.6% · Above median
Profitability
Return on equity (12 months)3.4% · Below median
Return on assets2.5% · Below median
Net margin (12 months)2.3% · Below median
Operating margin (12 months)4.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)23.4% · Above median
Dividend yield (12 months)2.9% · Above median
Balance sheet
Debt / equity0.65× · Highest 25%
Valuation Multiplesvs Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang Huakang Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/605077
Frequently asked questions
Is Zhejiang Huakang Pharmaceutical Co Ltd (605077) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ¥11.25 versus a price of ¥10.36, about +9% upside (fairly valued).
What is the fair value of 605077?
Our model-based fair value for Zhejiang Huakang Pharmaceutical Co Ltd is ¥11.25 (as of Nov 8, 2026), built from audited fundamentals. The current price: ¥10.36.
What is the quality score of 605077?
Zhejiang Huakang Pharmaceutical Co Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
Our model-based price target is the fair value of ¥11.25 (as of Nov 8, 2026) from 16 valuation models. Cautious scenario ¥8.44, optimistic scenario ¥14.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Huakang Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥11.25, about +9% upside versus a price of ¥10.36 (fairly valued). Cautious scenario ¥8.44, optimistic scenario ¥14.06. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
Zhejiang Huakang Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 4.8B CNY (latest available figure, as of Nov 8, 2026).
Does Zhejiang Huakang Pharmaceutical Co Ltd pay a dividend?
Zhejiang Huakang Pharmaceutical Co Ltd currently shows a dividend yield of 2.90% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Zhejiang Huakang Pharmaceutical Co Ltd (605077) and when is the ex-dividend date?
Zhejiang Huakang Pharmaceutical Co Ltd pays a dividend of ¥0.3 per share a year, a dividend yield of 2.9%. The last ex-dividend date was Jun 17, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 85.7% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Huakang Pharmaceutical Co Ltd it is ¥11.25 per share (as of Nov 8, 2026), against a price of ¥10.36. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Zhejiang Huakang Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 605077 trades below its calculated fair value: price ¥10.36, fair value ¥11.25, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 605077?
No. The price is what the market pays today (¥10.36); the fair value is what the company's own numbers justify (¥11.25). For Zhejiang Huakang Pharmaceutical Co Ltd the two are ¥0.8900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Huakang Pharmaceutical Co Ltd worth?
The market values Zhejiang Huakang Pharmaceutical Co Ltd at about 3.1B CNY (market capitalisation, as of Nov 8, 2026). Per share that is ¥10.36; our models calculate a fair value of ¥11.25 per share.
What do the bullish and bearish scenarios say about 605077?
Our models span a range for Zhejiang Huakang Pharmaceutical Co Ltd: cautious scenario ¥8.44, base ¥11.25, optimistic ¥14.06 per share (as of Nov 8, 2026, price ¥10.36). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 605077?
Zhejiang Huakang Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 29.6 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥11.25 is built from several models across several years. Other multiples: P/B 1.0, P/S 0.7, EV/EBITDA 7.3.
How solid is the balance sheet of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
Balance-sheet figures for Zhejiang Huakang Pharmaceutical Co Ltd (as of Nov 8, 2026): return on equity 3.4%, debt of 0.65 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 605077 from its 52-week high?
Zhejiang Huakang Pharmaceutical Co Ltd trades at ¥10.36, about 44% below its 52-week high of ¥18.55 and 5% above the low of ¥9.85 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.25 is for.
Which stocks are comparable to Zhejiang Huakang Pharmaceutical Co Ltd?
From the same area (Basic Materials) we also value BASF SE, Saudi Basic Industries Corporation, Dow Inc, Ningxia Baofeng Energy Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Huakang Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price ¥10.36, calculated fair value ¥11.25 (+9%), Quality Score 46/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 605077 calculated?
We run Zhejiang Huakang Pharmaceutical Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥11.25 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Zhejiang Huakang Pharmaceutical Co Ltd currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
The closing price on Nov 6, 2026 was ¥10.36. Our model-based fair value is ¥11.25, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Huakang Pharmaceutical Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Zhejiang Huakang Pharmaceutical Co Ltd
How large is the market capitalisation of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
The market capitalisation of Zhejiang Huakang Pharmaceutical Co Ltd is 3.1B CNY (≈ $471M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
The price-to-sales ratio of Zhejiang Huakang Pharmaceutical Co Ltd is 0.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
Earnings per share at Zhejiang Huakang Pharmaceutical Co Ltd are ¥0.3500 (price ÷ EPS = P/E 29.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
The dividend yield of Zhejiang Huakang Pharmaceutical Co Ltd is 2.9% (payout 85.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
The net margin of Zhejiang Huakang Pharmaceutical Co Ltd is 2.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
The return on equity (ROE) of Zhejiang Huakang Pharmaceutical Co Ltd is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
On an EBIT basis the return on assets of Zhejiang Huakang Pharmaceutical Co Ltd is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
The operating margin of Zhejiang Huakang Pharmaceutical Co Ltd is 4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
Revenue at Zhejiang Huakang Pharmaceutical Co Ltd is growing +23.4% versus a year earlier (3y avg +23.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang Huakang Pharmaceutical Co Ltd (605077)?
Earnings per share at Zhejiang Huakang Pharmaceutical Co Ltd are growing −60.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhejiang Huakang Pharmaceutical Co Ltd (605077) generate?
The free cash flow of Zhejiang Huakang Pharmaceutical Co Ltd is −59.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zhejiang Huakang Pharmaceutical Co Ltd (605077) carry?
The net debt of Zhejiang Huakang Pharmaceutical Co Ltd is 1.7B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zhejiang Huakang Pharmaceutical Co Ltd in the live analysis
One click puts Zhejiang Huakang Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026